A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Phase 2
Not yet recruiting
- Conditions
- Advanced Solid Tumour
- Interventions
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Nanjing Leads Biolabs Co.,Ltd
- Target Recruit Count
- 210
- Registration Number
- NCT06783647
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Xiangyang Central Hospital, Xiangyang, Hubei, China
🇨🇳Mianyang Central Hospital, Mianyang, Sichuan, China
A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma
Phase 1
Recruiting
- Conditions
- Advanced Neuroendocrine Carcinoma
- Interventions
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Nanjing Leads Biolabs Co.,Ltd
- Target Recruit Count
- 178
- Registration Number
- NCT06157827
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
🇨🇳Harbin Medical University Cancer Hospital, Ha'erbin, Heilongjiang, China
🇨🇳Shanxi Cancer hospital, Taiyuan, Shanxi, China
A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Nanjing Leads Biolabs Co.,Ltd
- Target Recruit Count
- 396
- Registration Number
- NCT05170958
- Locations
- 🇨🇳
Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Anyang Tumor Hospital, Anyang, Henan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath